Permax (pergolide) — the Parkinson’s Drug Pulled in 2007 for Quintupling Heart-Valve Damage

When the U.S. Food and Drug Administration announced on 29 March 2007 that the makers of pergolide had agreed to pull the drug from the American market, the action was filed as a routine post-market safety measure; the documented record shows that the fibrotic heart-valve mechanism that condemned Permax had been understood, in chemical detail, for years before the echocardiograms were read. Pergolide (marketed by Eli Lilly as Permax and approved by the FDA in 1988 as an adjunct to levodopa for Parkinson’s disease) was an ergot-derived dopamine agonist that relieved tremor and rigidity by stimulating dopamine receptors — but it also bound potently to the 5-HT2B serotonin receptor on heart-valve tissue, the identical target that had driven the valvulopathy behind the 1997 fen-phen catastrophe.

The gap between promise and harm was not an unforeseeable side effect. Two studies published side by side in The New England Journal of Medicine on 4 January 2007 closed the case. René Schade and colleagues, mining the U.K. General Practice Research Database cohort of 11,417 patients, found that pergolide carried an adjusted incidence-rate ratio of 7.1 (95% CI 2.3-22.3) for newly diagnosed cardiac-valve regurgitation. Renzo Zanettini’s echocardiographic study found clinically important (moderate-to-severe) regurgitation in 23.4 percent of pergolide patients versus 5.6 percent of controls — and, decisively, 0 percent in patients on non-ergot dopamine agonists, which do not hit the 5-HT2B receptor.

The verdict is therefore plain at the outset: a drug with no proven efficacy advantage over safer, mechanistically distinct alternatives kept hundreds of thousands of Parkinson’s patients exposed to a known fibrotic hazard years after the signal was legible. The FDA asked Lilly to add valvulopathy to the warnings section in 2003 and mandated a boxed warning in 2006; neither step removed the drug. Only the 2007 NEJM pair forced a withdrawal the pharmacology had argued for since at least 2002 — a quieter case than the blockbuster scandals, with no settlement fund and no Senate hearing, only a back-of-the-shelf agent kept in front-line use long after a receptor profile shared with a recalled diet drug had told clinicians exactly where to look.